Current therapeutic strategies for restrictive cardiomyopathy (RCM) primarily adhere to general heart failure management principles (Cimiotti et al., 2021), including angiotensin-converting enzyme inhibitors, β-blockers, calcium channel blockers, and anticoagulation. This evidence concerns the gene ACE and cardiomyopathy, familial restrictive, 1.